Literature DB >> 17325621

Potential impact of human papillomavirus vaccines on public STD clinic workloads and on opportunities to diagnose and treat other sexually transmitted diseases.

Amanda F Dempsey1, Laura A Koutsky, Matthew Golden.   

Abstract

BACKGROUND: Eradicating genital warts through HPV immunization could decrease STD clinic utilization but may result in missed opportunities to diagnose other STDs.
OBJECTIVES: To define the proportion of STD clinic visits attributable to HPV and to describe the prevalence of other STD diagnoses among visits for HPV-related presenting concerns. STUDY
DESIGN: Cross-sectional analysis of medical records (1994-2004) from a single STD clinic. Prevalences of STDs were calculated for male and female patients with and without HPV-related presenting concerns.
RESULTS: Of the 66,537 visits included in the study, 10.3% were HPV-related. Of the 3085 HPV-related "new problem" visits, only 281 non-HPV diagnoses were made, with nonspecific urethritis and CT being the most common diagnosis for males and females, respectively. Nearly 25% of the 14,574 follow-up visits were for HPV.
CONCLUSIONS: Newly developed HPV vaccines may substantially decrease public STD clinic workloads with little associated lost opportunity to diagnose and treat other STDs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17325621     DOI: 10.1097/01.olq.0000253337.62932.29

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   2.830


  3 in total

1.  Estimating the clinical benefits of vaccinating boys and girls against HPV-related diseases in Europe.

Authors:  Rémi Marty; Stéphane Roze; Xavier Bresse; Nathalie Largeron; Jayne Smith-Palmer
Journal:  BMC Cancer       Date:  2013-01-08       Impact factor: 4.430

2.  Awareness and knowledge of human papillomavirus (HPV) infection among high-risk men of Hispanic origin attending a sexually transmitted infection (STI) clinic.

Authors:  Vivian Colón-López; Ana P Ortiz; Lizbeth M Del Toro-Mejías; Hermes García; Michael C Clatts; Joel Palefsky
Journal:  BMC Infect Dis       Date:  2012-12-12       Impact factor: 3.090

3.  A comparative analysis of the epidemiological impact and disease cost-savings of HPV vaccines in France.

Authors:  Xavier Bresse; Marjorie Adam; Nathalie Largeron; Stephane Roze; Rémi Marty
Journal:  Hum Vaccin Immunother       Date:  2013-04-01       Impact factor: 3.452

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.